N-Acetyl Selank is an N-terminally acetylated analog of Selank sold as a research chemical, and no health authority has approved a human dosing regimen for it, so every figure attached to it is drawn from vendor inserts, preclinical work on the parent peptide, and self-reported anecdote rather than clinical standards. The published record describes two handling routes, intranasal and subcutaneous, with reported daily amounts for Selank-type peptides falling roughly between a couple hundred and 900 micrograms, and none of that rises above mechanism-and-anecdote evidence.
N-Acetyl Selank has no approved human dosing regimen in any major jurisdiction, so every reported dose, route, and schedule is descriptive of research-chemical handling drawn from vendor documentation and anecdote rather than clinical evidence.
The literature and vendor material converge on two routes, intranasal application and subcutaneous injection, with intranasal described far more often because a peptide of this size is broken down in the gut and the nasal mucosa offers a direct absorptive surface. Oral swallowing is treated as non-viable in the same sources, so the reported choice sits between needle-free nasal convenience and the more defined delivered amount of an injection.
| Reported route | Intranasal | Subcutaneous |
|---|---|---|
| Form | Drops or metered spray to nasal mucosa | Small reconstituted volume into subcutaneous tissue |
| Cited advantage | Needle-free, avoids gut breakdown | More defined delivered amount |
| Cited limitation | Imprecise per-dose absorption | Injection handling required |
| Frequency in sources | Most commonly described | Secondary route |
Vendor material and research reports describe two viable routes for N-Acetyl Selank, intranasal application as the dominant one and subcutaneous injection as a secondary route, while treating oral administration as non-viable because gut peptidases degrade the molecule.
The published rationale for the nasal route over swallowing rests on a plain pharmacological fact: proteases and stomach acid destroy an oral dose of this peptide class before it can absorb, leaving oral bioavailability negligible. The nasal mucosa sidesteps that first-pass breakdown, and a frequently cited but unproven claim holds that the nasal cavity may open a nose-to-brain path along olfactory and trigeminal tracts.
Oral dosing of Selank-type peptides is reported as effectively non-viable because gastrointestinal proteases and stomach acid leave oral bioavailability negligible, which is the documented reason intranasal delivery is favored despite its own incomplete and variable absorption.
Reported daily amounts for Selank-type peptides land roughly between a couple hundred micrograms and about 900 micrograms, usually split across the day, but the honest reading is that this is a summary of what sources say rather than a validated window. No peer-reviewed human trial has established an effective or safe dose, and acetylation is meant to change stability, so a figure quoted for Selank cannot be assumed to carry over to the acetylated form.
Reported daily amounts for Selank-type peptides span roughly 200 to 900 micrograms often split across the day, but these figures come from vendor pages, forums, and preclinical extrapolation with no peer-reviewed human trial, so no reliable human dose is established for the acetylated analog.
Reconstitution is documented as the step that turns a vial of lyophilized powder into a usable solution by adding a measured volume of diluent. Published protocols specify bacteriostatic water, which carries a small amount of benzyl alcohol, because the preservative slows microbial growth across the days a multi-use vial is drawn from, where plain sterile water suits only single immediate use.
Published reconstitution practice for lyophilized peptides describes dissolving the powder with bacteriostatic water, whose benzyl alcohol preservative supports multi-use draws over days, with the diluent volume setting the final concentration.
Working out a nasal-spray concentration is documented as linking the solution's strength to the roughly fixed volume a metered pump delivers per actuation, so the peptide in each spray is that spray volume multiplied by the concentration. The published caveat is blunt: the per-spray figure describes what leaves the bottle, not what reaches circulation, because runoff, swallowing, and mucociliary clearance make nasal delivery inefficient and variable.
Researchers are described estimating a nasal dose as the metered spray volume multiplied by the solution concentration, a figure that reflects what leaves the bottle rather than what is absorbed, since nasal delivery loses drug to runoff, swallowing, and mucociliary clearance.
Storage guidance in the published record splits sharply between the two forms: the sealed lyophilized powder is the durable one, kept frozen or refrigerated away from light and moisture, where it lasts far longer than any solution. Once reconstituted with bacteriostatic water the peptide becomes markedly less stable, described as refrigerated and used within a limited window of a few weeks before degradation is assumed to cut potency.
| Storage factor | Lyophilized powder | Reconstituted solution |
|---|---|---|
| Stability | More stable, durable form | Markedly less stable |
| Temperature | Frozen long-term or refrigerated | Refrigerated |
| Usable window | Far longer, months and beyond | A few weeks in most reports |
| Main degraders | Heat, light, moisture | Heat, freeze-thaw, light, contamination |
The published record treats the sealed lyophilized powder as the durable form kept frozen or refrigerated, while a solution reconstituted in bacteriostatic water is described as refrigerated and used within a limited window often cited as a few weeks before potency is assumed to fall.
Anecdotal accounts describe splitting the daily amount across two or three applications on the reasoning that a short-acting peptide is spread through the day, though some reports lean on the acetylated analog's claimed longer duration to justify fewer applications. Reported cycles run a few weeks of daily use followed by a break, with no consistent schedule emerging across accounts and no controlled evidence underneath any of it.
Frequency and cycling for N-Acetyl Selank are documented only as anecdote, with reports splitting the daily amount across two or three applications and running informal weeks-on, weeks-off cycles that rest on no controlled human evidence.
There is no approved human dosing regimen because N-Acetyl Selank has never completed the clinical development and regulatory review that would create one; in major jurisdictions it is not an approved drug and ships as a research chemical labeled not for human consumption. The parent peptide's longer regional study history does not confer approval on the acetylated analog, so any quoted dose, frequency, or concentration carries no regulatory or clinical backing.
N-Acetyl Selank has no approved human dosing regimen because it never completed the pharmacokinetic characterization, dose-finding trials, and regulatory review that approval requires, so every quoted dose, frequency, and concentration is an unverified figure with no clinical or regulatory backing.
Educational use only. This article describes what the published scientific and clinical literature reports about N-Acetyl Selank. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
